URGN stock icon

UroGen Pharma

12.12 USD
+0.02
0.17%
At close Nov 8, 4:00 PM EST
After hours
12.12
+0.00
0.00%
1 day
0.17%
5 days
-0.25%
1 month
-7.55%
3 months
-19.15%
6 months
-8.67%
Year to date
-20.32%
1 year
4.75%
5 years
-48.56%
 

About: UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in innovative solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.

Employees: 203

0
Funds holding %
of 6,759 funds
0
Analysts bullish %
of 12 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

175% more repeat investments, than reductions

Existing positions increased: 55 | Existing positions reduced: 20

60% more capital invested

Capital invested by funds: $419M [Q1] → $672M (+$253M) [Q2]

50% more funds holding in top 10

Funds holding in top 10: 2 [Q1] → 3 (+1) [Q2]

15.51% more ownership

Funds ownership: 81.9% [Q1] → 97.41% (+15.51%) [Q2]

15% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 20

3% more funds holding

Funds holding: 112 [Q1] → 115 (+3) [Q2]

25% less call options, than puts

Call options by funds: $3.18M | Put options by funds: $4.24M

Research analyst outlook

12 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$25
106%
upside
Avg. target
$42
250%
upside
High target
$64
428%
upside

12 analyst ratings

12 positive
100%
neutral
0%
negative
0%
EF Hutton
Jason Kolbert
50% 1-year accuracy
43 / 86 met price target
106%upside
$25
Buy
Maintained
6 Nov 2024
EF Hutton
Jason Kolbert
50% 1-year accuracy
43 / 86 met price target
106%upside
$25
Buy
Maintained
29 Oct 2024
EF Hutton
Jason Kolbert
50% 1-year accuracy
43 / 86 met price target
106%upside
$25
Buy
Maintained
21 Oct 2024
EF Hutton
Jason Kolbert
50% 1-year accuracy
43 / 86 met price target
106%upside
$25
Buy
Maintained
16 Oct 2024
Oppenheimer
Leland Gershell
64% 1-year accuracy
39 / 61 met price target
230%upside
$40
Outperform
Reiterated
16 Oct 2024

Financial journalist opinion

Based on 7 articles about URGN published over the past 30 days

Charts implemented using Lightweight Charts™